Funding medical researchers to accelerate into practice promising drugs and devices

The 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity is part of the MRFF and the Preventive and Public Health Research Initiative.

It will support Australian medical research and medical innovation projects that, through competitively selected national organisation/s partnering with small to medium enterprises (SMEs), accelerate into practice promising drugs and devices focused on cardiovascular disease and the complications of diabetes (types 1 and 2).

The successful independent organisation/s will be responsible for ensuring that the funding by each organisation:

• targets investment and related support through partnership projects to accelerate promising drug (topic A) or device (topic B) development projects
• promotes commercialisation of novel drugs and devices for cardiovascular disease and for complications of diabetes (types 1 and 2)
• provides a maximum of $1.5 million for each promising drug/device project
• leverages support (including co-funding) from partner organisations such as industry
• provides a minimum investment of $3 million into each of the following: cardiovascular disease; the disease-related complications in people with type 1 diabetes; and the disease-related complications in people with type 2 diabetes.

Reporting templates are available from the MRFF grants management webpage. The page also provides other resources for MRFF grant administration, including current policies and relevant forms and templates.